A Retrospective Analysis using Deep-Learning Models for Prediction of
  Survival Outcome and Benefit of Adjuvant Chemotherapy in Stage II/III
  Colorectal Cancer
  Most early-stage colorectal cancer (CRC) patients can be cured by surgery
alone, and only certain high-risk early-stage CRC patients benefit from
adjuvant chemotherapies. However, very few validated biomarkers are available
to accurately predict survival benefit from postoperative chemotherapy. We
developed a novel deep-learning algorithm (CRCNet) using whole-slide images
from Molecular and Cellular Oncology (MCO) to predict survival benefit of
adjuvant chemotherapy in stage II/III CRC. We validated CRCNet both internally
through cross-validation and externally using an independent cohort from The
Cancer Genome Atlas (TCGA). We showed that CRCNet can accurately predict not
only survival prognosis but also the treatment effect of adjuvant chemotherapy.
The CRCNet identified high-risk subgroup benefits from adjuvant chemotherapy
most and significant longer survival is observed among chemo-treated patients.
Conversely, minimal chemotherapy benefit is observed in the CRCNet low- and
medium-risk subgroups. Therefore, CRCNet can potentially be of great use in
guiding treatments for Stage II/III CRC.
